23-valent pneumococcal capsular polysaccharide vaccine: all 42 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• Preoperative Pneumococcal and Influenza Vaccination to Prevent Postoperative Pulmonary Infection in Patients Undergoing Lung Resection for Pulmonary Nodules or Lung CancerNot yet recruitingNCT07885540Phase 4
• A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy PeopleRecruitingNCT06044077Phase 3
• Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a LymphomaRecruitingNCT04460235Phase 4
• Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury PatientsRecruitingNCT02232191Phase 2
• A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 DiabetesCompletedNCT04481243Phase 4Results posted
• Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary PathologyCompletedNCT02787863Phase 4Results posted
• Vaccinating Children After ChemotherapyCompletedNCT02447718Phase 4Results posted
• Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)CompletedNCT02260882Phase 4Results posted
• Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)CompletedNCT02225587Phase 3Results posted
• Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and OlderCompletedNCT02218697Phase 3Results posted
• A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)CompletedNCT01734239Phase 3Results posted
• Immune Responses to Pneumococcal Vaccination Among HIV-infected SubjectsCompletedNCT00706550Not applicableResults posted
• Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPSCompletedNCT00574548Phase 3Results posted
• ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)CompletedNCT00535730Phase 3Results posted
• A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)CompletedNCT06708286Phase 2/3
• Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and AboveCompletedNCT05815264Phase 1
• Persistent Readiness Through Early Prediction Immunization StudyCompletedNCT05346302Early Phase 1
• Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic LeukemiaCompletedNCT05316831Phase 4
• PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2)Status unknownNCT04974294Phase 4
• Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic PatientsStatus unknownNCT04875858Phase 4
• A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the ElderlyCompletedNCT04701788Phase 4
• A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years OldCompletedNCT04700618Phase 4
• Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and AboveCompletedNCT04278248Phase 3
• Single Ascending Dose of ASP3772 Study in Japanese Healthy Male and Female Adults, and Single Ascending Dose Study of ASP3772 in Comparison With PPSV23 in Japanese Elderly Male and Female SubjectsCompletedNCT04265911Phase 1
• Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic DiseaseCompletedNCT03762824Phase 4
• Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected PatientsStatus unknownNCT03041051Phase 4
• Pneumococci and Hib Vaccination After Neurotrauma or NeurosurgeryCompletedNCT02806284Phase 2
• Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With AsthmaCompletedNCT02719379Phase 1
• Immune Response to Pneumococcal Vaccination in HIV Infected IndividualsCompletedNCT02515240Early Phase 1
• Polysaccharide Antibody Response StudyCompletedNCT02429531Phase 4
• Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy VolunteersCompletedNCT02279589Phase 2
• Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBDTerminatedNCT02255227Phase 2
• Effectiveness of the Pneumococcal Polysaccharide Vaccine in Military RecruitsCompletedNCT02079701Phase 4
• A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' AssaysCompletedNCT02072525Phase 4
• Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine ResponsesStatus unknownNCT02012309Not applicable
• Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected AdultsStatus unknownNCT00999739Phase 3
• Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus ErythematosusCompletedNCT00611663Phase 2/3
• Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With PrevnarCompletedNCT00594347Phase 3
• Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)CompletedNCT00496093Phase 3
• Pneumococcal Reference StandardCompletedNCT00479323Phase 1
• Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.TerminatedNCT00368186Phase 4
• Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.CompletedNCT00307008Phase 2

← 23-valent pneumococcal capsular polysaccharide vaccine overview